ArticleRSC advances2026
Bacterial ghosts embedded in natural hydrogels as drug delivery vehicles for cancer treatment.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hydrogels Activated with Plant Extracts/Bioactive Compounds for Cancer Treatment: From Design to Application.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing complexity of cancer treatment requires new drug delivery systems that improve the effectiveness of therapy and reduce adverse effects. This study explores the potential of using bacterial ghosts (BGs) in combination with hydrogels to develop a targeted drug delivery system for cancer treatment. BGs, based on non-pathogenic bacteria, offer several distinct advantages, including biocompatibility, maintenance of immunogenicity, and effective encapsulation of therapeutic agents. The BG-hydrogel system enhances stability and controlled release of encapsulated drugs, which enhances the therapeutic window of drugs. Herein, the BGs were loaded with the anticancer drug doxorubicin (DOX) and subsequently encapsulated in four different hydrogels, namely agarose, agar, aloe vera, and sodium alginate, to produce a Bacterial Ghost-Hydrogel System (BG-HS). The BGs, DOX-loaded BGs, hydrogels, and BG-HS morphologies were characterized by Scanning Electron Microscopy (SEM), revealing distinct structural features conducive to drug delivery applications. Detailed chemical analysis was conducted using Fourier Transform Infrared Spectroscopy (FTIR), confirming the presence of all individual components in the BG-HS. UV-vis spectroscopy demonstrated a pH-responsive drug-release profile attributed to hydrogel ionization in acidic and basic solutions. Compression testing was used to evaluate the mechanical integrity of hydrogels for
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.